Comparing two treatment plans for stage 2 rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study compares two standard treatment approaches for early-stage rectal cancer that has not spread. One group gets chemo and radiation before surgery, while the other gets chemo, radiation, and more chemo before surgery. The goal is to see which plan is more effective and has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with rectal cancer that has not spread to other parts of the body.
- Your tumor is at a stage called T3, meaning it has grown into the muscle layer of the rectum but not into nearby organs.
- You are 18 years or older.
- You are generally healthy enough to undergo treatment, with adequate kidney, liver, and blood function.
- You have not had chemotherapy or radiation to the pelvis before.
- You are able to have an MRI scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a “total neoadjuvant” approach, meaning you receive cancer treatment before surgery, to improve safety and effectiveness for rectal cancer. It may help by shrinking the tumor and planning a more effective operation, while researchers carefully track side effects.
This trial tests whether a full course of chemotherapy and radiation before any surgery (called total neoadjuvant therapy) can help you avoid surgery and preserve your rectum. It is for people with a specific early stage of rectal cancer that has not spread.
This trial compares two approaches for early-stage rectal cancer: chemotherapy plus local surgery versus standard chemoradiotherapy. It aims to see if less intensive treatment can work just as well, reducing side effects.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This study compares two approaches after early-stage rectal cancer is removed: either careful monitoring or a follow-up treatment with chemotherapy and radiation. The goal is to see which strategy works better to keep the cancer from returning.
This study compares two different schedules of radiation (a short course versus a longer course) followed by standard chemotherapy and immunotherapy for advanced rectal cancer. It aims to see which approach works best to shrink the tumor before surgery.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.